BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

21 articles for D Schmidt

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Similarity- and Substructure-Based Development ofßEBI
Philipps University Marburg
Potent vasopressin antagonists modified at the carboxy-terminal tripeptide tail.EBI
Research and Development Division
Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorß (PDGF-Rß) guided by water thermodynamics.EBI
Christian-Albrechts-University of Kiel
Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas.EBI
Bayer
Biphenyls as potent vitronectin receptor antagonists.EBI
Bayer
Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia.EBI
Merck Research Laboratories
GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a.EBI
Merck Research Laboratories
Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.EBI
Saarland University
GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a.EBI
Merck Research Laboratories
Anthranilic acid replacements in a niacin receptor agonist.EBI
Merck
Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.EBI
Saarland University
Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.EBI
Bayer Healthcare
Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer.EBI
Victoria University of Wellington
Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7.EBI
Syros Pharmaceuticals
Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.EBI
University
Combinatorial synthesis of cholesterol ester transfer protein-mRNA ligands and screening by nondenaturating gel-electrophoresis.EBI
Johann Wolfgang Goethe-Universit£T Frankfurt/Main
Potent antagonists of vasopressin antidiuretic activity that lack the beta,beta-cyclopentamethylene-beta-mercaptopropionic acid substitution at position 1.EBI
TBA
Potent vasopressin antagonists lacking the proline residue at position 7.EBI
TBA
C3-carbon linked glutarimide degronimers for target protein degradationBDB
C4 Therapeutics
Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereofBDB
Chia Tai Tianqing Pharmaceutical Group
Crystalline forms and processes for the preparation of cannabinoid receptor modulatorsBDB
Arena Pharmaceuticals